Skip to main content
Clinical Trials/NCT04688736
NCT04688736
Recruiting
Phase 2

A Prospective, Randomized, Double-blind Controlled Trial of Chlorpheniramine Pretransfusion Medication for Allergic Transfusion Reactions

Institute of Hematology & Blood Diseases Hospital, China4 sites in 1 country6,642 target enrollmentJanuary 1, 2021

Overview

Phase
Phase 2
Intervention
Placebo
Conditions
Allergic Transfusion Reaction
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Enrollment
6642
Locations
4
Primary Endpoint
The rate of allergic-transfusion reactions
Status
Recruiting
Last Updated
9 months ago

Overview

Brief Summary

This is a prospective, randomized, double-blind controlled trial to evaluate the efficacy of placebo versus chlorpheniramine for the prevention of allergic transfusion reactions.

Registry
clinicaltrials.gov
Start Date
January 1, 2021
End Date
June 30, 2027
Last Updated
9 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 18\~65 years old.
  • Subject is diagnosed with hematological disorder and requires blood product (i.e. suspended red blood cells, apheresis platelets, fresh frozen plasma) transfusions.
  • Subject can fully understand and voluntarily sign informed consent forms.

Exclusion Criteria

  • Subject with a history of allergic diseases.
  • Subject experienced at least 1 moderate/severe or 2 mild allergic reactions in the past.
  • Subject received glucocorticoid or allergy drugs within 24 hours before blood transfusion.
  • Subject transfused with washed RBC.
  • Received allo-HSCT transplantation before.
  • Subject with heart failure.
  • Subject suffered from sequelae of cardiovascular or cerebrovascular diseases.
  • Pregnant or nursing women.
  • Inability to understand or to follow study procedures.

Arms & Interventions

Placebo

Each recruited subject will oral 8mg placebo 20 minutes before blood transfusion.

Intervention: Placebo

Chlorpheniramine

Each recruited subject will oral 8mg chlorpheniramine 20 minutes before blood transfusion.

Intervention: Chlorpheniramine

Outcomes

Primary Outcomes

The rate of allergic-transfusion reactions

Time Frame: within 4 hours from the start of the transfusion

Study Sites (4)

Loading locations...

Similar Trials